497 related articles for article (PubMed ID: 24681846)
1. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
2. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
[TBL] [Abstract][Full Text] [Related]
3. Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy.
Davari K; Holland T; Prassmayer L; Longinotti G; Ganley KP; Pechilis LJ; Diaconu I; Nambiar PR; Magee MS; Schendel DJ; Sommermeyer D; Ellinger C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771892
[TBL] [Abstract][Full Text] [Related]
4. Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2.
Wagner C; Neumann F; Kubuschok B; Regitz E; Mischo A; Stevanovic S; Friedrich M; Schmidt W; Rammensee HG; Pfreundschuh M
Cancer Immun; 2003 Dec; 3():18. PubMed ID: 14677925
[TBL] [Abstract][Full Text] [Related]
5. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
[TBL] [Abstract][Full Text] [Related]
6. Expression and immunotherapeutic targeting of the SSX family of cancer-testis antigens in prostate cancer.
Smith HA; Cronk RJ; Lang JM; McNeel DG
Cancer Res; 2011 Nov; 71(21):6785-95. PubMed ID: 21880588
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
8. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.
Neumann F; Kubuschok B; Ertan K; Schormann C; Stevanovic S; Preuss KD; Schmidt W; Pfreundschuh M
Cancer Immunol Immunother; 2011 Sep; 60(9):1333-46. PubMed ID: 21630107
[TBL] [Abstract][Full Text] [Related]
9. Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.
Zhu S; Van den Eynde BJ; Coulie PG; Li YF; El-Gamil M; Rosenberg SA; Robbins PF
J Immunother; 2012; 35(9):680-8. PubMed ID: 23090077
[TBL] [Abstract][Full Text] [Related]
10. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
11. Vaccines targeting the cancer-testis antigen SSX-2 elicit HLA-A2 epitope-specific cytolytic T cells.
Smith HA; McNeel DG
J Immunother; 2011 Oct; 34(8):569-80. PubMed ID: 21904219
[TBL] [Abstract][Full Text] [Related]
12. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
13. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
Berdien B; Reinhard H; Meyer S; Spöck S; Kröger N; Atanackovic D; Fehse B
Hum Vaccin Immunother; 2013 Jun; 9(6):1205-16. PubMed ID: 23428899
[TBL] [Abstract][Full Text] [Related]
14. Differential presentation of tumor antigen-derived epitopes by MHC-class I and antigen-positive tumor cells.
Held G; Neumann F; Sturm C; Kaestner L; Dauth N; de Bruijn DR; Renner C; Lipp P; Pfreundschuh M
Int J Cancer; 2008 Oct; 123(8):1841-7. PubMed ID: 18688854
[TBL] [Abstract][Full Text] [Related]
15. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
16. Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer.
Zhang B; Ren Z; Zhao J; Zhu Y; Huang B; Xiao C; Zhang Y; Deng J; Mao L; Tang L; Lan D; Gao L; Zhang H; Chen G; Luo OJ
Theranostics; 2023; 13(13):4449-4468. PubMed ID: 37649599
[No Abstract] [Full Text] [Related]
17. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
Robbins PF; Li YF; El-Gamil M; Zhao Y; Wargo JA; Zheng Z; Xu H; Morgan RA; Feldman SA; Johnson LA; Bennett AD; Dunn SM; Mahon TM; Jakobsen BK; Rosenberg SA
J Immunol; 2008 May; 180(9):6116-31. PubMed ID: 18424733
[TBL] [Abstract][Full Text] [Related]
18. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
19. Identification of an HLA-DR-restricted peptide epitope with a promiscuous binding pattern derived from the cancer testis antigen HOM-MEL-40/SSX2.
Neumann F; Wagner C; Stevanovic S; Kubuschok B; Schormann C; Mischo A; Ertan K; Schmidt W; Pfreundschuh M
Int J Cancer; 2004 Nov; 112(4):661-8. PubMed ID: 15382048
[TBL] [Abstract][Full Text] [Related]
20. A rare population of tumor antigen-specific CD4
Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
